Genmab has experienced a multifaceted year with several notable events driving its stocks. The
EPKINLY trial results affected the price target negatively, however, factors like the
grant of restricted stock units and warrants to employees seemingly balanced out this effect. Genmab shares experienced a downtick causing concerns, but have benefited from a recent 8.0% rise following positive
DARZALEX royalties and a successful
Phase 3 epcoritamab test.
Citi and
Deutsche Bank indicated a strong outlook for Genmab, especially in relation to
AbbVie and oncology upside. The
biotech momentum reflected in the current stock pricing is touted as indicative of further growth. Despite some Phase 3 epcoritamab trial misses, the robust demand for
Darzalex is driving growth, making Genmab an attractive investment. Genmab has also delved into AI, partnering with Anthropic, and completed a significant $8bn acquisition of
Merus N.V.. However, a failed cancer drug trial and concerns over the valuation after strong one-year rally are leading to market fluctuations.
Genmab Stocks News Analytics from Thu, 01 May 2025 07:00:00 GMT to Sat, 31 Jan 2026 13:46:51 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor 4
